Clinical trial · Interventional
68Ga-FAPI-FS PET/CT and PET/MR in Pancreatic Cancer
Preliminary Study of 68Ga-FAPI-FS PET/CT in Patients With Pancreatic Cancer
NCT05875753CI-TRIAL-00066712unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a preliminary study of 68Ga-FAPI-FS PET/CT or PET/MR in patients with confirmed or suspicious pancreatic cancer. The goal is to determine the safety, biodistribution, and tumor uptake of 68Ga-FAPI-FS.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-FAPI-FS PET/CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 68Ga-FAPI-FS PET/CT
- description
- Each patient will receive one dose of 68Ga-FAPI-FS by intravenous route. Dedicated whole-body PET/CT imaging will be performed.
- interventionNames
- Diagnostic Test: 68Ga-FAPI-FS PET/CT
Primary outcomes (1)
- measure
- Adverse events after injection of 68Ga-FAPI-FS
- timeFrame
- From tracer injection to 3 hour post-injection
- description
- Adverse events will be recorded according to CTCEA v4.03
Secondary outcomes (7)
- measure
- SUVmax of liver on 68Ga-FAPI-FS
- timeFrame
- From study completion to 1 month after completion
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pancreatic cancer confirmed by histopathological results or pancreatic lesions with typical radiological appearance. 2. Expected survival of at least 3 months 3. ECOG ≤ 2 4. Written informed consent provided for participation in the trial 5. In the opinion of investigator, willing and able to comply with required study procedures. Exclusion Criteria: 1. Pregnancy or breastfeeding. 2. Severe claustrophobia.
References
Publications (0)
Data not yet available
No reference posted for this study.